NCT07436013 Comparing Revisional Laparoscopic Roux-en-Y Gastric Bypass Versus Ringed Revisional Roux-en-Y Gastric Bypass After Laparoscopic Sleeve Gastrectomy
| NCT ID | NCT07436013 |
| Status | Recruiting |
| Phase | — |
| Sponsor | General Committee of Teaching Hospitals and Institutes, Egypt |
| Condition | Revisional Bariatric Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2026-03-15 |
| Primary Completion | 2031-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2026-03-15 with a primary completion date of 2031-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Obesity remains a major global health challenge, with rising prevalence and significant metabolic, cardiovascular, and gastrointestinal comorbidities. Laparoscopic sleeve gastrectomy (LSG) has emerged as the most widely performed bariatric procedure due to its technical simplicity and satisfactory short- to mid-term results. However, a proportion of patients experience suboptimal weight loss, recurrent weight gain, or both. In this study, patients with recurrent weight gain of maximum weight loss or suboptimal weight loss or both following sleeve gastrectomy were included. Suboptimal weight loss is defined as total weight loss (TWL) of less than 20% of the preoperative weight and/or excess weight loss (EWL) of less than 50%, measured at least 12-18 months after the primary sleeve gastrectomy. Recurrent weight gain after sleeve gastrectomy is defined as an increase of ≥20% of the maximum weight loss (from nadir weight) or an increase in BMI of \>5, measured at least 24 months after the primary procedure.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-65 years. * Patients who experienced recurrent weight gain, suboptimal weight loss, or both within 12-24 months or more following sleeve gastrectomy. * Eligible and fit for bariatric surgery. * Willing to provide informed consent and adhere to follow-up. Exclusion Criteria: * Severe psychiatric disorders or uncontrolled substance abuse. * Pregnancy or planned pregnancy within 2 years post-surgery. * Chronic steroid use or immunosuppressive therapy. * Active malignancy or history of gastrointestinal cancer. * Severe cardiac or pulmonary disease precluding surgery. * Uncontrolled endocrine disorders (other than T2DM). * Inability to comply with follow-up or protocol requirements.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07436013 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Revisional Bariatric Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07436013 currently recruiting?
Yes, NCT07436013 is actively recruiting participants. Contact the research team at dr.mhany@gmail.com for enrollment information.
Where is the NCT07436013 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07436013 clinical trial?
NCT07436013 is sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. The trial plans to enroll 240 participants.